uMed raises £9.8m from Delin Ventures, AlbionVC, Playfair Capital and 11.2 Capital to expand clinical trial platform
The financing was backed by Delin Ventures, AlbionVC, Playfair Capital and 11.2 Capital to support international growth and research programmes.
uMed operates a health and research technology platform that connects healthcare providers with clinical studies. The system automates patient identification and data collection to support medical research.
London based healthtech company uMed has secured £9.8m in a new venture capital funding round to expand its clinical trial platform. The financing was supported by Delin Ventures, AlbionVC, Playfair Capital and 11.2 Capital.
The fresh capital will be deployed to scale up the company presence in North America and accelerate research programmes for targeted patient groups. This expansion follows a period of growth in the UK market where the platform has integrated with numerous general practices to facilitate large scale health studies.
From the founder
"We developed the uMed platform to help healthcare professionals more easily and efficiently run patient research and targeted care programmes at scale, improving outcomes for patients by mitigating care gaps and accelerating research. Our groundbreaking patient cohorts give researchers access to unique data and insights, accelerating development and access to new therapies, while dramatically reducing the cost of finding, engaging and collecting prospective data from patients."
Matt Wilson
Founder and CEO at uMed
Investor perspective
"At AlbionVC we are thrilled to continue partnering with Matt Wilson and his team to enable longitudinal research which has historically taken decades and cost millions of pounds. uMed’s technology is uniquely positioned to truly revolutionise how clinical research is conducted globally. The latest round of funding will continue to support the company’s US expansion and will further accelerate the next phase of growth on a path to global category leadership."
Molly Gilmartin
Investor, AlbionVC
Use of funds
- 01Expand into international markets
- 02Fund research and development
